Elevance Health, Inc. (ELV) Q2 2025 Earnings Call Transcript

Elevance Health (ELV) revised its full-year 2025 adjusted EPS guidance down to approximately $30, attributing the adjustment primarily to persistent elevated medical cost trends in its ACA business driven by increased morbidity and risk pool shifts, alongside slower-than-expected Medicaid rate alignment and higher member acuity. While Q2 adjusted EPS met expectations and Medicare Advantage trends remained consistent, the company is implementing disciplined pricing for 2026 across all segments, intensifying cost management, and leveraging technology to stabilize trends and rebuild long-term margin stability, acknowledging the need to address ongoing market recalibration.

Analysis

Elevance Health has revised its full-year 2025 adjusted EPS guidance downward to approximately $30, a significant adjustment driven by persistent, industry-wide pressures in its government-funded businesses. The primary drivers are elevated medical cost trends in the Affordable Care Act (ACA) segment, stemming from a market-wide increase in morbidity as healthier members exit and higher-acuity individuals from Medicaid join the risk pool. This is compounded by a slower-than-expected alignment of state reimbursement rates in the Medicaid business with the current high-acuity environment post-redetermination. The impact is quantified by a Q2 benefit expense ratio of 88.9%, an increase of 260 basis points year-over-year, with a full-year forecast of approximately 90%. While Q2 adjusted EPS of $8.84 met internal expectations, the outlook reflects a prudent view that these higher cost trends will persist. On a positive note, the Medicare Advantage business is exhibiting stable trends in line with expectations, and the Carelon segment continues to be a strong growth driver, with Carelon Services revenue and operating gain growing over 50%. Management is taking decisive action through disciplined 2026 pricing, aggressive cost management initiatives, and leveraging technology to combat aberrant billing, positioning for margin stabilization but acknowledging a prolonged recovery period.

Key Decisions for Investors

• Investors should anticipate continued margin pressure for the remainder of 2025, as the revised guidance embeds the expectation that elevated cost trends in ACA and Medicaid will not improve in the near term.
• The effectiveness of 2026 rate filings will be a critical catalyst; watch for commentary on whether pricing in the ACA and Medicaid segments adequately captures the new, higher baseline of member acuity and trend.
• Monitor the performance of the Carelon segment, as its strong growth (over 20% in Rx revenue, over 50% in Services) serves as a crucial offset to margin volatility in the core insurance businesses and is central to the company's long-term strategy.
• Pay close attention to management's execution on cost control initiatives and capital allocation, particularly the signaled intent for more opportunistic share repurchases, which could provide support for the stock's valuation amid operational headwinds.